Literature DB >> 24776093

Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic.

Eftychia Koumarianou1, Tatiana A Slastnikova2, Marek Pruszynski1, Andrey A Rosenkranz2, Ganesan Vaidyanathan1, Alexander S Sobolev2, Michael R Zalutsky3.   

Abstract

INTRODUCTION: Modular nanotransporters (MNTs) are vehicles designed to transport drugs from the cell surface via receptor-mediated endocytosis and endosomal escape to nucleus. Hence their conjugation to Auger electron emitters, can cause severe cell killing, by nuclear localization. Herein we evaluate the use of MNT as a platform for targeted radiotherapy with (67)Ga.
METHODS: EGF was the targeting ligand on the MNT, and NOTA was selected for its radiolabeling with (67)Ga. In the radiolabeling study we dealt with the precipitation of MNT (pI 5.7) at the labeling pH (4.5-5.5) of (67)Ga. Cellular and nuclei uptake of (67)Ga-NOTA-MNT by the A431 cell line was determined. Its specific cytotoxicity was compared to that of (67)Ga-EDTA, (67)Ga-NOTA-BSA and (67)Ga-NOTA-hEGF, in A431 and U87MGWTT, cell lines, by clonogenic assay. Dosimetry studies were also performed.
RESULTS: (67)Ga-NOTA-MNT was produced with 90% yield and specific activity of 25.6mCi/mg. The in vitro kinetics revealed an increased uptake over 24h. 55% of the internalized radioactivity was detected in the nuclei at 1h. The cytotoxicity of (67)Ga-NOTA-MNT on A431 cell line was 17 and 385-fold higher when compared to non-specific (67)Ga-NOTA-BSA and (67)Ga-EDTA. While its cytotoxic potency was 13 and 72-fold higher when compared to (67)Ga-NOTA-hEGF in the A431 and the U87MGWTT cell lines, respectively, validating its nuclear localization. The absorbed dose, for 63% cell killing, was 8Gy, confirming the high specific index of (67)Ga.
CONCLUSION: These results demonstrate the feasibility of using MNT as a platform for single cell kill targeted radiotherapy by Auger electron emitters.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (67)Ga; Auger electron emitter; EGFR; Modular nanotransporter; Radionuclide therapy

Mesh:

Substances:

Year:  2014        PMID: 24776093      PMCID: PMC4048709          DOI: 10.1016/j.nucmedbio.2014.03.026

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  37 in total

1.  A comparison of 4 radionuclides conjugated to antibodies for single-cell kill.

Authors:  Rosana B Michel; Martin W Brechbiel; M Jules Mattes
Journal:  J Nucl Med       Date:  2003-04       Impact factor: 10.057

2.  A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).

Authors:  G Vaidyanathan; D J Affleck; J Li; P Welsh; M R Zalutsky
Journal:  Bioconjug Chem       Date:  2001 May-Jun       Impact factor: 4.774

3.  Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Authors:  Michael R Zalutsky; Abraham Boskovitz; Chien-Tsun Kuan; Charles N Pegram; Joanne Ayriss; Carol J Wikstrand; Anne F Buckley; Eric S Lipp; James E Herndon; Roger E McLendon; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

4.  Targeting cancer cells by novel engineered modular transporters.

Authors:  Dinara G Gilyazova; Andrey A Rosenkranz; Pavel V Gulak; Vladimir G Lunin; Olga V Sergienko; Yuri V Khramtsov; Kirill N Timofeyev; Mikhail A Grin; Andrey F Mironov; Andrey B Rubin; Georgii P Georgiev; Alexander S Sobolev
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

5.  Antibody-based cancer treatment with ultra-short range Auger electron-emitting radionuclides: dual receptor and DNA targeting strategies.

Authors:  Tom C Karagiannis
Journal:  Hell J Nucl Med       Date:  2007 Sep-Dec       Impact factor: 1.102

6.  Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons.

Authors:  Jean-Pierre Pouget; Lore Santoro; Laure Raymond; Nicolas Chouin; Manuel Bardiès; Caroline Bascoul-Mollevi; Helena Huguet; David Azria; Pierre-Olivier Kotzki; Monique Pèlegrin; Eric Vivès; André Pèlegrin
Journal:  Radiat Res       Date:  2008-08       Impact factor: 2.841

7.  Dynamics of proteasome distribution in living cells.

Authors:  E A Reits; A M Benham; B Plougastel; J Neefjes; J Trowsdale
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

8.  Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.

Authors:  Paul Chen; Judy Wang; Kristin Hope; Liqing Jin; John Dick; Ross Cameron; Joseph Brandwein; Mark Minden; Raymond M Reilly
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

9.  Improved iodine radiolabels for monoclonal antibody therapy.

Authors:  Rhona Stein; Serengulam V Govindan; M Jules Mattes; Susan Chen; Linda Reed; Guy Newsome; Bill J McBride; Gary L Griffiths; Hans J Hansen; David M Goldenberg
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

Review 10.  Targeting the nucleus: an overview of Auger-electron radionuclide therapy.

Authors:  Bart Cornelissen; Katherine A Vallis
Journal:  Curr Drug Discov Technol       Date:  2010-12
View more
  17 in total

1.  A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.

Authors:  Raghu Raghavan; Roger W Howell; Michael R Zalutsky
Journal:  Biomed Phys Eng Express       Date:  2017-05-05

2.  Antitumor efficacy of Auger electron emitter 111In delivered by modular nanotransporter into the nuclei of cells with folate receptor overexpression.

Authors:  A A Rosenkranz; T A Slastnikova; Yu V Khramtsov; T S Karyagina; G P Georgiev; A S Sobolev
Journal:  Dokl Biochem Biophys       Date:  2017-05-17       Impact factor: 0.788

Review 3.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

4.  Stabilization of Modular Nanotransporters by Embedding Hemin in Them in a New Strain with Heme Receptor Expression.

Authors:  Yu V Khramtsov; A V Ulasov; A A Rosenkranz; G P Georgiev; A S Sobolev
Journal:  Dokl Biochem Biophys       Date:  2020-04-27       Impact factor: 0.788

5.  In vitro cytotoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab.

Authors:  Muhamad Faiz Bin Othman; Elise Verger; Ines Costa; Meena Tanapirakgul; Margaret S Cooper; Cinzia Imberti; Valerie J Lewington; Philip J Blower; Samantha Y A Terry
Journal:  Nucl Med Biol       Date:  2019-12-13       Impact factor: 2.408

Review 6.  Auger: The future of precision medicine.

Authors:  Giacomo Pirovano; Thomas C Wilson; Thomas Reiner
Journal:  Nucl Med Biol       Date:  2021-03-19       Impact factor: 2.408

7.  Development and evaluation of a new modular nanotransporter for drug delivery into nuclei of pathological cells expressing folate receptors.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Yuri V Khramtsov; Tatiana S Karyagina; Sergey A Ovechko; Alexander S Sobolev
Journal:  Drug Des Devel Ther       Date:  2017-04-26       Impact factor: 4.162

8.  Preparation, cytotoxicity, and in vivo antitumor efficacy of 111In-labeled modular nanotransporters.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Natalia B Morozova; Maria S Vorontsova; Vasiliy M Petriev; Tatiana N Lupanova; Alexey V Ulasov; Michael R Zalutsky; Raisa I Yakubovskaya; Alexander S Sobolev
Journal:  Int J Nanomedicine       Date:  2017-01-10

9.  Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression.

Authors:  Andrey A Rosenkranz; Tatiana A Slastnikova; Tatiana A Karmakova; Maria S Vorontsova; Natalia B Morozova; Vasiliy M Petriev; Alexey S Abrosimov; Yuri V Khramtsov; Tatiana N Lupanova; Alexey V Ulasov; Raisa I Yakubovskaya; Georgii P Georgiev; Alexander S Sobolev
Journal:  Front Pharmacol       Date:  2018-11-19       Impact factor: 5.810

10.  Validation of the plasmid study to relate DNA damaging effects of radionuclides to those from external beam radiotherapy.

Authors:  Elise Verger; Jordan Cheng; Vittorio de Santis; Madeleine Iafrate; Jessica A Jackson; Cinzia Imberti; Gilbert O Fruhwirth; Philip J Blower; Michelle T Ma; Daniel R Burnham; Samantha Y A Terry
Journal:  Nucl Med Biol       Date:  2021-06-15       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.